1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79:813–829.
Article
2. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998; 352:799–805.
Article
3. Godwin JD 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975; 36:560–569.
4. Yang K, Cheng YS, Yang JJ, Jiang X, Guo JX. Primary hepatic neuroendocrine tumor with multiple liver metastases: a case report with review of the literature. World J Gastroenterol. 2015; 21:3132–3138.
Article
5. Qiu MJ, Chen YB, Bi NR, Yang SL, He XX, Xiong ZF. Comparative clinical analysis of gastroenteropancreatic neuroendocrine carcinomas with liver metastasis and primary hepatic neuroendocrine carcinomas. Dis Markers. 2018; 2018:9191639.
Article
6. Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med. 1987; 82(5B):4–16.
Article
7. Huang YQ, Xu F, Yang JM, Huang B. Primary hepatic neuroendocrine carcinoma: clinical analysis of 11 cases. Hepatobiliary Pancreat Dis Int. 2010; 9:44–48.
8. Oberg K. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. Ann Oncol. 1999; 10 Suppl 2:S3–S8.
9. Shetty PK, Baliga SV, Balaiah K, Gnana PS. Primary hepatic neuroendocrine tumor: an unusual cystic presentation. Indian J Pathol Microbiol. 2010; 53:760–762.
Article
10. Kellock T, Tuong B, Harris AC, Yoshida E. Diagnostic imaging of primary hepatic neuroendocrine tumors: a case and discussion of the literature. Case Rep Radiol. 2014; 2014:156491.
Article
11. Wang LX, Liu K, Lin GW, Jiang T. Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathology. Cancer Imaging. 2015; 15:13.
Article
12. Kim JE, Lee WJ, Kim SH, Rhim H, Song HJ, Park CK. Three-phase helical computed tomographic findings of hepatic neuroendocrine tumors: pathologic correlation with revised WHO classification. J Comput Assist Tomogr. 2011; 35:697–702.
13. Li RK, Zhao J, Rao SX, Chen CZ, Zeng MS, Qiang JW. Primary hepatic neuroendocrine carcinoma: MR imaging findings including preliminary observation on diffusion-weighted imaging. Abdom Imaging. 2013; 38:1269–1276.
Article
14. Yalav O, Ulku A, Akçam TA, Demiryurek H, Doran F. Primary hepatic neuroendocrine tumor: five cases with different preoperative diagnoses. Turk J Gastroenterol. 2012; 23:272–278.
Article
15. Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao Paulo). 2012; 67 Suppl 1:109–112.
Article
16. Rocca A, Calise F, Marino G, Montagnani S, Cinelli M, Amato B, et al. Primary giant hepatic neuroendocrine carcinoma: a case report. Int J Surg. 2014; 12 Suppl 1:S218–S221.
Article
17. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab. 2005; 19:265–276.
18. Gabriel S, Garrigue P, Dahan L, Castinetti F, Sebag F, Baumstark K, et al. Prospective evaluation of
68Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clin Endocrinol (Oxf). 2018; DOI:
10.1111/cen.13745. [Epub].
19. Hwang S, Lee YJ, Lee SG, Kim CW, Kim KH, Ahn CS, et al. Surgical treatment of primary neuroendocrine tumors of the liver. J Gastrointest Surg. 2008; 12:725–730.
Article
20. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002; 40:2–11.
Article
21. Bahra M, Jacob D, Pascher A, Plockinger U, Kristiansen G, Neuhaus P, et al. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. J Gastroenterol Hepatol. 2007; 22:930–935.
Article
22. Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. Ann Surg Oncol. 2003; 10:1171–1175.
Article
23. Zhang A, Xiang J, Zhang M, Zheng S. Primary hepatic carcinoid tumours: clinical features with an emphasis on carcinoid syndrome and recurrence. J Int Med Res. 2008; 36:848–859.
Article
24. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997; 225:355–364.
25. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998; 66:1307–1312.
26. Fenwick SW, Wyatt JI, Toogood GJ, Lodge JP. Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg. 2004; 239:210–219.
Article
27. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis. Digestion. 2003; 68:94–101.
28. Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M. Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg. 2007; 11:1680–1685.
Article
29. Krishnamurthy SC, Dutta V, Pai SA, Kane SV, Jagannath P, Desouza LJ, et al. Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. J Surg Oncol. 1996; 62:218–221.
Article